NorthWest Biotherapeutics Inc (NWBO)

[Rkmatters]

They still would have had 5 years of survival on patients to graph. Only the last few patients were enrolled in the final months of 2015. Waiting gives them 100% of patients passed 5 years.

Right now as statistic stands there are well less than 10% of patients who survive with a GBM diagnosis passed 5 years.

We already know that a large percentage of this study’s ITT population survived over 40 months, something like 30%. Now remember one third of this study got placebo upfront and only crossed over treatment upon progression. So that 30% is impressive. We will get to see what percentage of their study survives over 60 months (treatment and upon progression treatment) and my bet is it will be a significant improvement to the typical 5%.
Until they do the statistical analysis they won’t lock data on survival. They only locked progression free survival data with the most recent data lock. Do remember their are two data locks for two endpoints. Data on survival continues to accrue inside the study data (to which they can chart KM curve) once they officially end the study and do the statistical data analysis on both.

Stay well